DE3855575D1 - Wasserlösliche Camptothecin-Analoge - Google Patents

Wasserlösliche Camptothecin-Analoge

Info

Publication number
DE3855575D1
DE3855575D1 DE3855575T DE3855575T DE3855575D1 DE 3855575 D1 DE3855575 D1 DE 3855575D1 DE 3855575 T DE3855575 T DE 3855575T DE 3855575 T DE3855575 T DE 3855575T DE 3855575 D1 DE3855575 D1 DE 3855575D1
Authority
DE
Germany
Prior art keywords
alkyl
hydrogen
water soluble
ch2nh2
formyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3855575T
Other languages
English (en)
Other versions
DE3855575T2 (de
Inventor
Jeffrey Charles Boehm
Randall Keith Johnson
Sidney Michael Hecht
William Dennis Kingsbury
Kenneth George Holden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of DE3855575D1 publication Critical patent/DE3855575D1/de
Application granted granted Critical
Publication of DE3855575T2 publication Critical patent/DE3855575T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
DE3855575T 1987-12-01 1988-11-30 Wasserlösliche Camptothecin-Analoge Expired - Lifetime DE3855575T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12714887A 1987-12-01 1987-12-01

Publications (2)

Publication Number Publication Date
DE3855575D1 true DE3855575D1 (de) 1996-10-31
DE3855575T2 DE3855575T2 (de) 1997-03-20

Family

ID=22428545

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1997175017 Active DE19775017I2 (de) 1987-12-01 1988-11-30 Wasserloesliche Camptothecin-Analoge
DE3855575T Expired - Lifetime DE3855575T2 (de) 1987-12-01 1988-11-30 Wasserlösliche Camptothecin-Analoge

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1997175017 Active DE19775017I2 (de) 1987-12-01 1988-11-30 Wasserloesliche Camptothecin-Analoge

Country Status (25)

Country Link
US (1) US5004758A (de)
EP (1) EP0321122B1 (de)
JP (1) JPH0633268B2 (de)
KR (1) KR930009357B1 (de)
CN (3) CN1027265C (de)
AT (1) ATE143368T1 (de)
AU (1) AU612735B2 (de)
CA (1) CA1308102C (de)
CY (1) CY2017A (de)
DE (2) DE19775017I2 (de)
DK (1) DK173034B1 (de)
ES (1) ES2094721T3 (de)
FI (1) FI89923C (de)
GR (1) GR3021990T3 (de)
HK (1) HK81097A (de)
IE (1) IE74873B1 (de)
IL (1) IL88517A (de)
LU (2) LU90026I2 (de)
MX (1) MX9203744A (de)
NL (1) NL970017I2 (de)
NO (2) NO170487C (de)
NZ (1) NZ227124A (de)
PT (1) PT89111B (de)
SG (1) SG66254A1 (de)
ZA (1) ZA888938B (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122526A (en) * 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5106742A (en) * 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5227380A (en) * 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US5180722A (en) * 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US5049668A (en) * 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
JP2684104B2 (ja) * 1990-02-09 1997-12-03 株式会社ヤクルト本社 新規なカンプトテシン誘導体
DE69131775T2 (de) * 1990-09-28 2000-04-20 Smithkline Beecham Corp. Verfahren zur Herstellung wasserlöslicher Camptothecinanaloge, sowie die Verbindungen 10-Hydroxy-11-C(1-6)-alkoxycamptothecin
US5883255A (en) * 1990-10-31 1999-03-16 Smithkline Beecham Corporation Substituted indolizino 1,2-b!quinolinones
EP0572563A4 (en) * 1991-02-21 1993-12-29 Smithkline Beecham Corporation Treatment of esophageal cancer
WO1992014471A1 (en) * 1991-02-21 1992-09-03 Smithkline Beecham Corporation Treatment of non-small cell lung carcinoma
EP0572557B1 (de) * 1991-02-21 2009-10-07 SmithKline Beecham Corporation Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs
EP0540099B1 (de) * 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Wasserlösliche Camptothecinderivate
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
AU671605B2 (en) 1991-11-15 1996-09-05 Smithkline Beecham Corporation Combination chemotherapy
JPH07501818A (ja) * 1991-12-10 1995-02-23 スミスクライン・ビーチャム・コーポレイション 結腸直腸癌の治療
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US5446047A (en) * 1992-07-23 1995-08-29 Sloan-Kettering Institute For Cancer Research Camptothecin analogues
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
WO1994004160A1 (en) * 1992-08-21 1994-03-03 Dana Farber Cancer Institute Treatment of human viral infections
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5674872A (en) * 1993-08-20 1997-10-07 Smithkline Beecham Corporation Treatment of ovarian cancer
WO1995011020A1 (en) * 1993-10-20 1995-04-27 Enzon, Inc. 2'- and/or 7- substituted taxoids
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
DE69531611T2 (de) * 1994-04-28 2004-02-26 Bionumerik Pharmaceuticals, Inc., San Antonio Lactone-stabile camptothecin oder 7 - ethyl camptothecin - formulierung in dimethylisosorbid oder dimethylacetamid
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US6504029B1 (en) * 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5663177A (en) * 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5670500A (en) * 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5942386A (en) * 1995-06-07 1999-08-24 Thomas Jefferson University Anti-fungal agents and methods of identifying and using the same
WO1997019085A1 (en) * 1995-11-22 1997-05-29 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
BR9711319B1 (pt) * 1996-08-19 2009-08-11 derivados de camptotecina altamente lipofìlicos.
US6013505A (en) * 1996-10-08 2000-01-11 Smithkline Beecham Corporation Topoisomerase I
US6025156A (en) * 1996-10-15 2000-02-15 Smithkline Beecham Corporation Topoisomerase III
US5962303A (en) 1996-10-15 1999-10-05 Smithkline Beecham Corporation Topoisomerase III
US6559309B2 (en) 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
ATE329903T1 (de) * 1997-02-14 2006-07-15 Bionumerik Pharmaceuticals Inc Hochgradig lipophile camptothecin-derivate
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6046209A (en) * 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
CA2243363C (en) * 1997-07-17 2002-01-29 Kuraray Co., Ltd. Process for producing chromans
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
CA2340020A1 (fr) * 1998-08-05 2000-02-17 Aventis Pharma S.A. Utilisation de derives de la camptothecine, avec une toxicite gastro-intestinale reduite
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
FR2801309B1 (fr) * 1999-11-18 2002-01-04 Adir Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
CZ298259B6 (cs) 2000-02-28 2007-08-08 Aventis Pharma S. A. Farmaceutická kombinace k lécení rakoviny obsahující CPT-11 a capecitabin
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
AR027687A1 (es) * 2000-03-22 2003-04-09 Yakult Honsha Kk Procedimiento para preparar camptotecina
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
EP1333820A2 (de) 2000-10-27 2003-08-13 Aventis Pharma S.A. Zusammensetzungen zur behandlung von krebs, die camptothecin und stilbenverderivate enthalten
AU2002219815A1 (en) * 2000-11-14 2002-05-27 Emerald Biostructures, Inc. Chrystal compositions comprising topoisomerase i
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
ATE493993T1 (de) * 2002-03-26 2011-01-15 Tsutomu Kagiya Chromanol glucoside zur verbesserung der chemischen krebsbehandlung
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
WO2004055020A1 (en) * 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Process for the direct preparation of 5-alkoxy and 5-acyloxy analogues of campthothecins or mappicene ketones
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
AU2003223109A1 (en) * 2003-03-31 2004-10-25 Council Of Scientific And Industrial Research Process for preparing topotecan from 10-hydroxy-4-(s) camptothecin
CN100406460C (zh) * 2003-11-10 2008-07-30 中国科学院上海药物研究所 喜树碱的新衍生物、制备方法和用途
TWI333492B (en) * 2003-11-12 2010-11-21 Smithkline Beecham Cork Ltd Crystalline topotecan hydrochloride product and preparation thereof
ATE507240T1 (de) * 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
AU2005244768B2 (en) * 2004-04-27 2011-06-09 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US20050267141A1 (en) 2004-05-28 2005-12-01 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
US7122700B2 (en) * 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
WO2006069344A2 (en) 2004-12-22 2006-06-29 Rutgers, The State University Of New Jersey Controlled release hydrogels
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
WO2006090931A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の抗癌剤との新規併用
ATE540698T1 (de) * 2005-07-14 2012-01-15 Wellstat Biologics Corp Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen
US8349863B2 (en) * 2005-10-10 2013-01-08 Cipla Limited Crystalline polymorphic form of a camptothecin analogue
US7786134B2 (en) 2005-12-16 2010-08-31 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds, compositions and related methods
US7547785B2 (en) 2005-12-26 2009-06-16 Dr. Reddy's Laboratories Limited Process for preparing topotecan
WO2007085370A1 (en) * 2006-01-25 2007-08-02 Heidelberg Pharma Ag 9-(dimethylamino)-methyl-10-hydroxy-camptothecin lipidester derivatives
CN101033230B (zh) * 2006-03-10 2010-12-08 中国科学院上海药物研究所 一类喜树碱衍生物及其应用
CA2658015A1 (en) 2006-03-30 2007-10-11 Diatos S.A. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
WO2007127839A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US20110028536A1 (en) * 2006-08-18 2011-02-03 Gjerset Ruth A Methods and compositions for topoisomerase i modulated tumor suppression
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US7977483B2 (en) * 2007-04-11 2011-07-12 Scinopharm Taiwan, Ltd. Process for making topotecan
US20080255175A1 (en) * 2007-04-16 2008-10-16 Lam Marina K Anti-cancer agents, compositions and methods of treating cancers
JP5315337B2 (ja) * 2007-04-19 2013-10-16 シノファーム タイワン，リミテッド トポテカン塩酸塩の結晶形およびその製造方法
US8026249B2 (en) * 2007-09-14 2011-09-27 Deutena Pharmaceuticals, Inc. Deuterium-enriched topotecan
ITMI20072268A1 (it) 2007-12-04 2009-06-05 Antibioticos Spa Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione
CN102046634B (zh) * 2008-05-29 2013-04-24 日本迈科洛生物制药有限公司 喜树碱衍生物的制备方法
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010075517A2 (en) * 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
RU2447076C1 (ru) * 2010-12-09 2012-04-10 Закрытое Акционерное Общество "Фарм-Синтез" Способ получения топотекана
JP6013359B2 (ja) 2010-12-17 2016-10-25 ノバルティス アーゲー 組合せ
WO2012083197A1 (en) 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
WO2012106302A1 (en) 2011-02-01 2012-08-09 Glaxo Wellcome Manufacturing Pte Ltd Combination
PL2750683T3 (pl) 2011-10-03 2018-10-31 Mx Adjuvac Ab Nanocząsteczki, sposób ich otrzymywania i ich zastosowanie jako nośnik dla związków amfipatycznych cząsteczek hydrofobowych w dziedzinach medycyny włączając leczenie raka i związki powiązane z żywnością
PL235836B1 (pl) * 2012-10-25 2020-11-02 Inst Chemii Organicznej Polskiej Akademii Nauk Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
CN103113381B (zh) * 2013-02-26 2014-12-10 大连理工大学 系列水溶性羟基喜树碱环烷胺醇衍生物及其制法与用途
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
US10308719B2 (en) 2015-01-26 2019-06-04 The University Of Chicago IL13Rα2 binding agents and use thereof in cancer treatment
WO2016123143A1 (en) 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
CN108135917B (zh) 2015-09-25 2021-07-09 Zy医疗 基于包含多糖-维生素缀合物的颗粒的药物制剂
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
PT3622953T (pt) * 2016-05-17 2021-04-21 Scandion Oncology As Tratamento combinado do cancro
CA3071599A1 (en) 2017-08-07 2019-02-14 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
EP3669890A1 (de) 2018-12-18 2020-06-24 Croda International PLC Filamentöse nanopartikel mit impfstoffadjuvanswirkung
WO2020191342A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
CA3134056A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
WO2020210376A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
BR112021021663A2 (pt) 2019-04-30 2022-05-17 Inst De Medicina Molecular Joao Lobo Antunes Inibidores da via rank em combinação com inibidores de cdk
US20220305081A1 (en) 2019-06-24 2022-09-29 Amgen Inc. Inhibitions of sirp-gamma for cancer treatment
US20220265659A1 (en) 2019-09-02 2022-08-25 Inserm (Institut National De La Santé Et De Al Recherche Médicale) Methods and compositions for treating pax6-deficiency related disease
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
CN116478174A (zh) * 2022-07-29 2023-07-25 杭州爱科瑞思生物医药有限公司 喜树碱衍生物及其制备方法和应用
CN117462548A (zh) * 2023-03-09 2024-01-30 兰州大学 喜树碱类衍生物在制备治疗膀胱癌药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4342776A (en) * 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58134095A (ja) * 1982-02-05 1983-08-10 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS58154584A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd ５位ヒドロキシ置換カンプトテシン誘導体の製造法
JPS5951289A (ja) * 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体
JPS59227884A (ja) * 1983-06-09 1984-12-21 Yakult Honsha Co Ltd 新規な７−ヒドロキシアルキルカンプトテシン誘導体
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4775759A (en) * 1984-11-27 1988-10-04 The United States Of America As Represented By The Department Of Health And Human Services Synthesis and utilization of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy 6β-fluoromorphinans (foxy and cyclofoxy) as (18F)-labeled opioid ligands for position emission transaxial tomography (PETT)
US4820816A (en) * 1985-08-02 1989-04-11 President And Fellows Of Harvard College 3-trifuoromethylsulfonyloxy-substituted 1-carbacephalosporins as intermediates for antibiotics
JPH0615546B2 (ja) * 1986-02-24 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
JP3431931B2 (ja) * 1992-07-16 2003-07-28 旭電化工業株式会社 銅及び銅合金の表面処理方法

Also Published As

Publication number Publication date
CN1027265C (zh) 1995-01-04
CN1083817A (zh) 1994-03-16
CN1034724A (zh) 1989-08-16
CA1308102C (en) 1992-09-29
NO1998003I1 (no) 1998-01-15
ATE143368T1 (de) 1996-10-15
NO885352L (no) 1989-06-02
NO885352D0 (no) 1988-11-30
PT89111B (pt) 1994-01-31
LU90053I2 (fr) 1997-07-01
NZ227124A (en) 1991-12-23
DK663688D0 (da) 1988-11-28
MX9203744A (es) 1992-09-01
FI89923B (fi) 1993-08-31
IE74873B1 (en) 1997-08-13
LU90026I2 (fr) 1997-04-22
CN1035380C (zh) 1997-07-09
ZA888938B (en) 1990-03-28
ES2094721T3 (es) 1997-02-01
CY2017A (en) 1998-02-20
SG66254A1 (en) 1999-07-20
FI885569A0 (fi) 1988-11-30
EP0321122A2 (de) 1989-06-21
KR890009934A (ko) 1989-08-05
FI89923C (fi) 1993-12-10
CN1087637A (zh) 1994-06-08
IL88517A0 (en) 1989-06-30
IE883576L (en) 1989-06-01
DK663688A (da) 1989-06-02
DK173034B1 (da) 1999-11-29
FI885569A (fi) 1989-06-02
US5004758A (en) 1991-04-02
IL88517A (en) 1994-10-07
PT89111A (pt) 1989-12-29
EP0321122A3 (de) 1990-12-27
DE3855575T2 (de) 1997-03-20
NL970017I2 (nl) 1997-09-01
KR930009357B1 (ko) 1993-09-28
NO170487C (no) 1992-10-21
JPH01186893A (ja) 1989-07-26
AU612735B2 (en) 1991-07-18
CN1037574C (zh) 1998-03-04
GR3021990T3 (en) 1997-03-31
EP0321122B1 (de) 1996-09-25
HK81097A (en) 1997-06-20
JPH0633268B2 (ja) 1994-05-02
DE19775017I2 (de) 2002-11-07
NO170487B (no) 1992-07-13
AU2639488A (en) 1989-06-01
NL970017I1 (nl) 1997-06-02

Similar Documents

Publication Publication Date Title
DE3855575D1 (de) Wasserlösliche Camptothecin-Analoge
ATE127801T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung.
DK162519C (da) Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat indeholdende forbindelserne
MY105158A (en) Substituted 4-aminoquinoline derivatives as gastric acid secretion inhibutors.
ES8207180A1 (es) Procedimiento de fabricacion de derivados de tetrahidro-5,67,7a 4h-tieno (3,2-c) piridinona-2 .
AU6216886A (en) Substituted 2-cyano-2-phenyl ethyl-amine
EP0186023A3 (de) Gallensäurederivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
MX9806229A (es) Derivados de benzo(c)quinolicina, su preparacion y uso como inhibidores de la 5alfa-reductasas.
NZ216334A (en) Spiro imidazolone derivatives and pharmaceutical composition
ATE30724T1 (de) Cephalosporinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten.
EP0341837A3 (de) Glutamsäurederivate
DE3665593D1 (en) Peptide immunostimulants
IT1205114B (it) 2-selenometil-1,4-diidropiridine,procedimento per la loro preparazione e composizioni farmaceutiche che le contengono
ES8707939A1 (es) Procedimiento para preparar derivados de n-carboxialquil-2--oxo-3-diaril-5,6-triazinas

Legal Events

Date Code Title Description
V448 Application of spc

Free format text: PRODUCT NAME: HYCAMTIN - TOPOTECAN HYDROCHLORYD; REGISTRATION NO/DATE: EU/1/96/027/001, EU/1/96/027/002; 19961112

Spc suppl protection certif: 197 75 017

Filing date: 19970502

8364 No opposition during term of opposition
V457 Spc granted

Free format text: PRODUCT NAME: HYCAMTIN - TOPOTECAN HYDROCHLORYD; REGISTRATION NO/DATE: EU/1/96/027/001, EU/1/96/027/002; 19961112

Spc suppl protection certif: 197 75 017

Filing date: 19970502

R071 Expiry of right

Free format text: PRODUCT NAME: TOPOTECAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ, HYDRAT ODER SOLVAT DAVON; NAT. REGISTRATION NO/DATE: EU/1/96/027/001-002 19961112; FIRST REGISTRATION: CH/LI 53857 19961016

Spc suppl protection certif: 19775017

Filing date: 19970502

Expiry date: 20081201

Extension date: 20111016

Effective date: 20111017

R071 Expiry of right

Free format text: PRODUCT NAME: NELARABINE UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE, ETHER, ESTER ODER SALZE SOLCHER ESTER; REGISTRATION NO/DATE: EU/1/07/403/001 20070822

Spc suppl protection certif: 122008000003

Filing date: 20080108

Expiry date: 20080528

Extension date: 20130527

Effective date: 20130528